Minimal residual disease and imaging‐guided consolidation strategies in newly diagnosed and relapsed refractory multiple myeloma-Reference-Cited by-同舟云学术

Minimal residual disease and imaging‐guided consolidation strategies in newly diagnosed and relapsed refractory multiple myeloma

Published:2022-05-18 Issue:3 Volume:198 Page:515-522
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Böckle David¹^ORCID,Tabares Paula¹²,Zhou Xiang¹,Schimanski Sven¹,Steinhardt Maximilian J.¹,Bittrich Max¹,Seebacher Elena¹²,Ulbrich Maria¹²,Wilnit Amy¹²,Metz Corona³,Heidemeier Anke³,Bley Thorsten³,Werner Rudolf⁴,Buck Andreas⁴,Einsele Hermann¹^ORCID,Kortüm K. Martin¹^ORCID,Beilhack Andreas¹²,Rasche Leo¹⁵

Affiliation:

1. Division of Oncology and Hematology, Department of Internal Medicine II Würzburg University Hospital Würzburg Germany

2. Interdisciplinary Center for Clinical Research Laboratory Würzburg University Hospital Würzburg Germany

3. Department of Radiology Würzburg University Hospital Würzburg Germany

4. Department of Nuclear Medicine Würzburg University Hospital Würzburg Germany

5. Mildred Scheel Early Career Center Würzburg University Hospital Würzburg Germany

Funder

Bundesministerium für Bildung und Forschung

Deutsche Krebshilfe

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.18249

Reference35 articles.

1. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

2. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma

3. Evaluation of sustained minimal residual disease (MRD) negativity in relapsed/refractory multiple myeloma (RRMM) patients (Pts) treated with daratumumab in combination with lenalidomide plus dexamethasone (D‐Rd) or bortezomib plus dexamethasone (D‐Vd): analysis of pollux and castor;Avet‐Loiseau H;Blood,2018

4. Ten Color Multiparameter Flow Cytometry in Bone Marrow and Apheresis Products for Assessment and Outcome Prediction in Multiple Myeloma Patients

5. Minimal residual disease in multiple myeloma: final analysis of the IFM2009 trial;Avet‐Loiseau H;Blood,2017

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Symptomatic Myeloma;PET Clinics;2024-10

2. Role of minimal residual disease assessment in multiple myeloma;Haematologica;2024-02-08

3. Contribution of post-transplantation therapy to sustained MRD negativity in multiple myeloma: a retrospective analysis;International Journal of Hematology;2023-12-16

4. MRD and Plasma Cell Dynamics after CAR T-cell Therapy in Myeloma;Blood Cancer Discovery;2023-09-01

5. New Developments in Myeloma Treatment and Response Assessment;Journal of Nuclear Medicine;2023-08-17